Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Progressive Metastatic Prostate Cancer”

83 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 83 results

Testing effectiveness (Phase 2)Study completedNCT01288911
What this trial is testing

Enzalutamide Versus Bicalutamide in Castrate Men With Metastatic Prostate Cancer

Who this might be right for
Prostatic Neoplasms
Astellas Pharma Inc 375
Testing effectiveness (Phase 2)Active Not RecruitingNCT04506567
What this trial is testing

Fractionated and Multiple Dose 225Ac-J591 for Progressive mCRPC

Who this might be right for
Prostate Cancer
Weill Medical College of Cornell University 60
Large-scale testing (Phase 3)Ended earlyNCT00676650
What this trial is testing

Sunitinib Plus Prednisone In Patients With Metastatic Castration-Resistant Prostate Cancer After Failure Of Docetaxel Chemotherapy

Who this might be right for
Prostatic Neoplasms
Pfizer 873
Post-approval studies (Phase 4)Study completedNCT03641560
What this trial is testing

A Safety and Efficacy Study of Enzalutamide in Indian Patients With Progressive Metastatic Castration-Resistant Prostate Cancer (mCRPC) Previously Treated With Docetaxel-Based Chemotherapy

Who this might be right for
Metastatic Castration Resistant Prostate Cancer
Astellas Pharma Inc 52
Testing effectiveness (Phase 2)Looking for participantsNCT06004661
What this trial is testing

Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Normal Renal Function

Who this might be right for
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Novartis Pharmaceuticals 20
Early research (Phase 1)Ended earlyNCT02349139
What this trial is testing

Safety, Preliminary Efficacy and Pharmacokinetics of ASN001 in Metastatic Castrate Resistant Prostate Cancer

Who this might be right for
Cancer of the ProstateNeoplasms, ProstateProstate Cancer+3 more
Asana BioSciences 27
Early research (Phase 1)Study completedNCT01303705
What this trial is testing

Anti-OX40, Cyclophosphamide (CTX) and Radiation in Patients With Progressive Metastatic Prostate Cancer

Who this might be right for
Metastatic Prostate CancerCancer of the ProstateProstate Cancer
Providence Health & Services 13
Testing effectiveness (Phase 2)Study completedNCT00599313
What this trial is testing

Phase II Sunitinib Prog Met AIPC

Who this might be right for
Metastatic Prostate Cancer
US Oncology Research 36
Testing effectiveness (Phase 2)Active Not RecruitingNCT05114746
What this trial is testing

Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer in Japan

Who this might be right for
Prostate Cancer
Novartis Pharmaceuticals 94
Testing effectiveness (Phase 2)Study completedNCT00390468
What this trial is testing

Tandutinib in Treating Patients With Progressive Prostate Cancer and Bone Metastases

Who this might be right for
Metastatic CancerPainProstate Cancer
National Cancer Institute (NCI) 18
Not applicableStudy completedNCT00002981
What this trial is testing

PET Scan in Treating Patients With Metastatic Prostate Cancer

Who this might be right for
Prostate Cancer
Memorial Sloan Kettering Cancer Center 173
Testing effectiveness (Phase 2)Active Not RecruitingNCT06894511
What this trial is testing

An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI Versus AAA617 in PSMA Positive First-line mCRPC

Who this might be right for
Metastatic Castration Resistant Prostate Cancer (mCRPC)
Novartis Pharmaceuticals 7
Testing effectiveness (Phase 2)Ended earlyNCT02933801
What this trial is testing

ODM-201 Maintenance Therapy in Patients With mCRPC Previously Treated With Novel Hormonal Agents.

Who this might be right for
Prostate Cancer MetastaticProstate Cancer
Swiss Cancer Institute 92
Testing effectiveness (Phase 2)Active Not RecruitingNCT05658003
What this trial is testing

A Study Evaluating [177Lu]Lu-PSMA-617 vs. a Change of Androgen Receptor-directed Therapy in Taxane Treatment Naive Chinese Male Patients With Progressive Metastatic Castrate Resistant Prostate Cancer

Who this might be right for
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Novartis Pharmaceuticals 63
Early research (Phase 1)Study completedNCT01692262
What this trial is testing

Investigating Safety, Tolerability and Efficacy of AZD5363 in Prostate Cancer.

Who this might be right for
Metastatic Castrate-Resistant Prostate Cancer (mCRPC),Efficacy,Safety and Tolerability,+3 more
AstraZeneca 59
Testing effectiveness (Phase 2)Study completedNCT02225704
What this trial is testing

Radium-223 in Combination With Enzalutamide

Who this might be right for
Prostate Cancer
Cancer Trials Ireland 45
Testing effectiveness (Phase 2)Ended earlyNCT00080782
What this trial is testing

Doxorubicin and Strontium-89 With or Without Celecoxib in Treating Patients With Progressive Androgen-Independent Prostate Cancer and Bone Metastases

Who this might be right for
Metastatic CancerProstate Cancer
M.D. Anderson Cancer Center 14
Not applicableStudy completedNCT02025413
What this trial is testing

Isolation of Circulating Tumor Cells Using a Novel EMT-Based Capture Method

Who this might be right for
Metastatic Progressive Castration-resistant Prostate CancerMetastatic Progressive Breast Cancer
Duke University 46
Testing effectiveness (Phase 2)Study completedNCT02445976
What this trial is testing

Once-daily Oral Seviteronel in Patients With Castration-Resistant Prostate Cancer Progressing on Enzalutamide or Abiraterone.

Who this might be right for
Prostate Cancer
Innocrin Pharmaceutical 197
Large-scale testing (Phase 3)Study completedNCT01707966
What this trial is testing

Orteronel Maintenance Therapy in Patients With Metastatic Castration Resistant Prostate Cancer and Non-progressive Disease After First-line Docetaxel Therapy

Who this might be right for
Prostate Cancer
Swiss Cancer Institute 47
Load More Results